These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1032 related articles for article (PubMed ID: 25784798)

  • 21. Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure.
    Marazzi G; Iellamo F; Volterrani M; Caminiti G; Madonna M; Arisi G; Massaro R; Righi D; Rosano GM
    Am J Cardiol; 2011 Jan; 107(2):215-9. PubMed ID: 21129714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: implications for beta-blocker selection.
    Chin BS; Gibbs CR; Blann AD; Lip GY
    Clin Sci (Lond); 2003 Oct; 105(4):507-12. PubMed ID: 12841846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure.
    Konishi M; Haraguchi G; Kimura S; Inagaki H; Kawabata M; Hachiya H; Hirao K; Isobe M
    Circ J; 2010 Jun; 74(6):1127-34. PubMed ID: 20354334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study.
    Riccioni G; Masciocco L; Benvenuto A; Saracino P; De Viti D; Massari F; Meliota G; Buta F; Speziale G
    Pharmacology; 2013; 92(5-6):276-80. PubMed ID: 24296869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.
    Düngen HD; Apostolovic S; Inkrot S; Tahirovic E; Töpper A; Mehrhof F; Prettin C; Putnikovic B; Neskovic AN; Krotin M; Sakac D; Lainscak M; Edelmann F; Wachter R; Rau T; Eschenhagen T; Doehner W; Anker SD; Waagstein F; Herrmann-Lingen C; Gelbrich G; Dietz R;
    Eur J Heart Fail; 2011 Jun; 13(6):670-80. PubMed ID: 21429992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure.
    Kovacić D; Marinsek M; Gobec L; Lainscak M; Podbregar M
    Clin Res Cardiol; 2008 Jan; 97(1):24-31. PubMed ID: 17694376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: results of CIBIS II.
    Krum H; Bailey M; Meyer W; Verkenne P; Dargie H; Lechat P; Anker S
    Cardiology; 2007; 108(1):28-34. PubMed ID: 16960445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus.
    Garcia-Egido A; Andrey JL; Puerto JL; Aranda RM; Pedrosa MJ; López-Sáez JB; Rosety M; Gomez F
    Int J Clin Pract; 2015 May; 69(5):550-9. PubMed ID: 25707623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Carvedilol versus β1-selective β blockers (bisoprolol, metoprolol, and nebivolol) in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    Seo GW; Kim DK; Kim KH; Seol SH; Jin HY; Yang TH; Ahn Y; Jeong MH; Song PS; Kim DI;
    Am J Cardiol; 2015 Nov; 116(10):1502-8. PubMed ID: 26520013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronotropic incompentence and functional capacity in chronic heart failure: no role of β-blockers and β-blocker dose.
    Magrì D; Palermo P; Cauti FM; Contini M; Farina S; Cattadori G; Apostolo A; Salvioni E; Magini A; Vignati C; Alimento M; Sciomer S; Bussotti M; Agostoni P
    Cardiovasc Ther; 2012 Apr; 30(2):100-8. PubMed ID: 20553283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial.
    Contini M; Apostolo A; Cattadori G; Paolillo S; Iorio A; Bertella E; Salvioni E; Alimento M; Farina S; Palermo P; Loguercio M; Mantegazza V; Karsten M; Sciomer S; Magrì D; Fiorentini C; Agostoni P
    Int J Cardiol; 2013 Oct; 168(3):2134-40. PubMed ID: 23506636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [COPD patients with heart failure: no concern about the beta blocker!].
    Stiefelhagen P
    MMW Fortschr Med; 2012 Apr; 154(6):26. PubMed ID: 22642023
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure.
    Podbregar M; Voga G
    J Card Fail; 2002 Dec; 8(6):369-78. PubMed ID: 12528088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heart rate following short-term beta-blocker titration predicts all-cause mortality in elderly chronic heart failure patients: insights from the CIBIS-ELD trial.
    Düngen HD; Musial-Bright L; Inkrot S; Apostolović S; Edelmann F; Lainščak M; Sekularac N; Störk S; Tahirovic E; Tscholl V; Krackhardt F; Loncar G; Trippel TD; Gelbrich G
    Eur J Heart Fail; 2014 Aug; 16(8):907-14. PubMed ID: 24935020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction.
    Choi KH; Lee GY; Choi JO; Jeon ES; Lee HY; Lee SE; Kim JJ; Chae SC; Baek SH; Kang SM; Choi DJ; Yoo BS; Kim KH; Cho MC; Park HY; Oh BH
    Korean J Intern Med; 2019 Sep; 34(5):1030-1039. PubMed ID: 30317846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension.
    Stefan MS; Rothberg MB; Priya A; Pekow PS; Au DH; Lindenauer PK
    Thorax; 2012 Nov; 67(11):977-84. PubMed ID: 22941975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial.
    Petersen M; Andersen JT; Jimenez-Solem E; Broedbaek K; Afzal S; Nyegaard M; Børglum AD; Stender S; Torp-Pedersen C; Køber L; Poulsen HE
    Pharmacogenet Genomics; 2012 Oct; 22(10):709-15. PubMed ID: 22760495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
    Krum H; Mohacsi P; Katus HA; Tendera M; Rouleau JL; Fowler MB; Coats AJ; Roecker EB; Packer M;
    Am Heart J; 2006 Jan; 151(1):55-61. PubMed ID: 16368292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure.
    Sirak TE; Jelic S; Le Jemtel TH
    J Am Coll Cardiol; 2004 Aug; 44(3):497-502. PubMed ID: 15358010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET.
    Swedberg K; Olsson LG; Charlesworth A; Cleland J; Hanrath P; Komajda M; Metra M; Torp-Pedersen C; Poole-Wilson P
    Eur Heart J; 2005 Jul; 26(13):1303-8. PubMed ID: 15767288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.